JeffreyGroup, which focuses on efforts targeting Latin audiences, has named Claudia Mejia-Haffner MD of the firm’s New York office and head of the U.S. Hispanic practice. She’ll manage a roster of clients including Clorox, Jose Cuervo, T-Mobile, and Fox Hispanic Media. Mejia-Haffner was previously VP of Axis, the IPG firm targeting Hispanic and African-American audiences and has served as a VP at Hill+Knowlton Strategies.
Michele Galen has been named the head of communications at pharmaceutical giant Novartis. She was previously VP and global head of comms and advocacy for the company, based in Basel, Switzerland. She joined the company in 2001.
Viacom Entertainment Group has promoted Tim Bruno to SVP of event production, talent development, and studio relations. Bruno will add production duties to a number of awards shows and events to his list of duties and will continue to lead talent development and motion picture studio relations. Viacom Group brands include Comedy Central, Spike TV, and TV Land.
The Public Relations Society of America’s nonprofit organization, the PRSA Foundation, has added four trustees to the 2012 board: Helen Ostrawski, former CEO of Porter Novelli, current adjunct professor at New York University and APCO Worldwide adviser; Travis Parman, principal of The Parman Group; Judith Phair, president of PhairAdvantage Communications; and Kirk Stewart, EVP at APCO Worldwide. Lou Capozzi, former MSLGroup chair, will serve another year as president of the board.
The Institute for Public Relations has also added five corporate communications officers to its board of trustees: Richard Jones, SVP and chief comms officer of Guardian Life; Torod Neptune, corporate VP of Verizon Communications; Adrian Rodriguez, SVP and chief comms officer of MetLife; Oscar Suris, EVP of corp comms at Wells Fargo; and Richard White, VP of corp comms at Wisconsin Energy. They will serve through 2014. Board co-chairs Mike Fernandez, corporate VP of corporate affairs at Cargill, and Matthew Gonring, VP of corp comms at Jackson will continue in their roles.
[image: Novartis’ Michelle Galen]